English Polski
Vol 18, No 2 (2023)
Review paper
Published online: 2022-09-18

open access

Page views 2309
Article views/downloads 713
Get Citation

Connect on Social Media

Connect on Social Media

CA-125: a promising biomarker in heart failure. Summary of the current knowledge

Maria Sawościan1, Małgorzata Lelonek1
DOI: 10.5603/FC.a2022.0052
Folia Cardiologica 2023;18(2):65-70.


The search for suitable biomarkers for monitoring and treatment of patients with heart failure (HF) is still ongoing. The novel biomarker — carbohydrate antigen 125 (CA-125), used commonly so far in oncology, was proven to be useful in assessing congestion and inflammation in heart failure. Its elevated values are also strongly correlated with impaired right ventricle function. What is more, the increased level of CA-125 correlates positively with HF readmissions and a higher risk of death. Hence, that makes a need to tailor a potential treatment strategy, which was performed in the CHANCE-HF study. Despite the advantages of this biomarker, such as convenient access or significantly low cost of assessments, conducting multicentre and international studies is necessary to implement suitable guidelines.

Article available in PDF format

View PDF Download PDF file


  1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
  2. Tymińska A, Kapłon-Cieślicka A, Filipiak KJ. Niewydolność serca — nowe biomarkery na horyzoncie? Choroby Serca i Naczyń. 2018; 15(4): 232–244.
  3. Boorsma EM, Ter Maaten JM, Damman K, et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol. 2020; 17(10): 641–655.
  4. Woźniak-Wiśniewska A, Błażejewski J, Bujak R, et al. The value of cancer antigen 125 (Ca 125) and copeptin as markers in patients with advanced heart failure. Folia Cardiologica. 2017; 12(6): 537–542.
  5. Marcus C, Maxwell G, Darcy K, et al. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. Journal of Cancer. 2014; 5(1): 25–30.
  6. Kumric M, Kurir TT, Bozic J, et al. Carbohydrate antigen 125: a biomarker at the crossroads of congestion and inflammation in heart failure. Card Fail Rev. 2021; 7: e19.
  7. Hung CL, Hung TC, Lai YH, et al. Beyond malignancy: the role of carbohydrate antigen 125 in heart failure. Biomark Res. 2013; 1(1): 25.
  8. Vizzardi E, D'Aloia A, Curnis A, et al. Carbohydrate antigen 125: a new biomarker in heart failure. Cardiol Rev. 2013; 21(1): 23–26.
  9. Girerd N, Seronde MF, Coiro S, et al. INI-CRCT, Great Network, and the EF-HF Group. Integrative assessment of congestion in Heart failure throughout the patient journey. JACC Heart Fail. 2018; 6(4): 273–285.
  10. Núñez J, Miñana G, Núñez E, et al. Clinical utility of antigen carbohydrate 125 in heart failure. Heart Fail Rev. 2014; 19(5): 575–584.
  11. Huang F, Chen J, Liu Y, et al. New mechanism of elevated CA125 in heart failure: the mechanical stress and inflammatory stimuli initiate CA125 synthesis. Med Hypotheses. 2012; 79(3): 381–383.
  12. Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, et al. CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol. 1994; 47(3): 263–265.
  13. Bulska-Będkowska W, Chełmecka E, Owczarek AJ, et al. CA125 as a marker of heart failure in the older women: population-based analysis. J Clin Med. 2019; 8(5): 607.
  14. Colombo PC, Onat D, Harxhi A, et al. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J. 2014; 35(7): 448–454.
  15. Turgut O, Tandogan I, Yilmaz MB, et al. CA125 levels among patients with advanced heart failure: an emerging independent predictor for survival. Int J Cardiol. 2010; 145(1): 71.
  16. Soler M, Miñana G, Santas E, et al. CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation. Int J Cardiol. 2020; 308: 54–59.
  17. Santas E, Miñana G, Palau P, et al. Tricuspid regurgitation and mortality risk across left ventricular systolic function in acute heart failure. Circ J. 2015; 79(7): 1526–1533.
  18. Kouris NT, Zacharos ID, Kontogianni DD, et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail. 2005; 7(2): 199–203.
  19. D'Aloia A, Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol. 2003; 41(10): 1805–1811.
  20. Zhang Yi, Jin Qi, Zhao Z, et al. Carbohydrate antigen 125 is a biomarker of the severity and prognosis of pulmonary hypertension. Front Cardiovasc Med. 2021; 8: 699904.
  21. Núñez J, de la Espriella R, Miñana G, et al. Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review. Eur J Heart Fail. 2021; 23(9): 1445–1457.
  22. Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, et al. Novel biomarkers of heart failure. Adv Clin Chem. 2017; 79: 93–152.
  23. Llàcer P, Gallardo MÁ, Palau P, et al. Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure. Med Clin (Barc). 2021; 156(12): 589–594.
  24. Pellicori P, Zhang J, Cuthbert J, et al. High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovasc Res. 2020; 116(1): 91–100.
  25. Yafasova A, Butt JH, Rørth R. Troponin: an important prognostic biomarker in patients with heart failure and reduced ejection fraction? Eur J Heart Fail. 2021; 23(9): 1539–1540.
  26. Melchio R, Rinaldi G, Testa E, et al. Red cell distribution width predicts mid-term prognosis in patients hospitalized with acute heart failure: the RDW in Acute Heart Failure (RE-AHF) study. Intern Emerg Med. 2019; 14(2): 239–247.
  27. Piek A, Du W, de Boer RA, et al. Novel heart failure biomarkers: why do we fail to exploit their potential? Crit Rev Clin Lab Sci. 2018; 55(4): 246–263.
  28. Ponikowska B, Iwanek G, Zdanowicz A, et al. Biomarkers of myocardial injury and remodeling in heart failure. J Pers Med. 2022; 12(5): 799.
  29. Lourenço P, Cunha FM, Elias C, et al. CA-125 variation in acute heart failure: a single-centre analysis. ESC Heart Fail. 2022; 9(2): 1018–1026.
  30. Wang XY, Zhang F, Zhang C, et al. The biomarkers for acute myocardial infarction and heart failure. Biomed Res Int. 2020; 2020: 2018035.
  31. Al Aseri ZA, Habib SS, Marzouk A. Predictive value of high sensitivity C-reactive protein on progression to heart failure occurring after the first myocardial infarction. Vasc Health Risk Manag. 2019; 15: 221–227.
  32. Núñez J, Llàcer P, Bertomeu-González V, et al. Carbohydrate antigen 125-guided therapy in acute heart failure. JACC Heart Fail. 2016; 4(11): 833–843.
  33. Núñez J, Bayés-Genís A, Revuelta-López E, et al. Clinical role of CA125 in worsening heart failure: a BIOSTAT-CHF study subanalysis. JACC Heart Fail. 2020; 8(5): 386–397.
  34. Sawościan M, Lelonek M. Terapia inhibitorami kontransportera sodowo-glukozowego 2 – nie tylko dla diabetologów. Folia Cardiologica. 2021; 16(6): 389–393.
  35. de la Espriella-Juan R, Miñana G, Santas E, et al. Effects of empagliflozin on CA 125 trajectory in patients with chronic congestive heart failure. Int J Cardiol. 2021; 339: 102–105.
  36. Zhuang J, Faggiano P, Li Qi, et al. Insights into the clinical implications of carbohydrate antigen 125 as a biomarker of heart failure: a meta-analysis and systematic review of published studies. J Cardiovasc Med (Hagerstown). 2014; 15(12): 864–872.
  37. Li KaH, Gong M, Li G, et al. Cancer antigen-125 and outcomes in acute heart failure: a systematic review and meta-analysis. Heart Asia. 2018; 10(2): e011044.
  38. Lorenzo M, Palau P, Llàcer P, et al. Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure. Eur J Intern Med. 2021; 92: 94–99.